Key Points Bristol Myers Squibb maintains a deep portfolio of oncology and immunology treatments while generating high levels of free cash flow. Eli Lilly and is seeing explosive revenue growth driven by its market-leading metabolic and injectable drug platforms. Should you prioritize value and dividends or high-octane pharmaceutical growth for your 2026 portfolio? 10 stocks we like better than Bristol Myers Squibb › Bristol Myers Squibb (NYSE:BMY) and Eli Lilly & Co (NYSE:LLY) represent two different paths in the healthcare market. Choosing between a deep-value dividend payer and a high-growth pharmaceutical juggernaut is the ultimate dilemma for investors today.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.